Robert Wong, VP and Chief Accounting Officer of Retension Pharmaceuticals, Inc., reported the grant of 25,000 stock options on November 2, 2026, in a statement of changes in beneficial ownership filed with the SEC on November 4, 2026.

Key Highlights

  • Reporting person: Robert Wong, VP and Chief Accounting Officer of Retension Pharmaceuticals, Inc. (NASDAQ:RTSN)
  • Transaction date: November 2, 2026, with the filing submitted November 4, 2026
  • Award granted: 25,000 stock options (right to buy) with an exercise price of $11.30 per share
  • Expiration date: November 2, 2036, giving the options a 10-year term
  • Vesting schedule: 25% vests on the first anniversary of the grant date, with the remainder vesting in 36 equal monthly increments thereafter, subject to continued service
  • Post-transaction holdings: Wong beneficially owns 25,000 derivative securities following the reported transaction, held directly
  • Price paid: $0, as reported in the filing for the derivative security price

Stock Option Grant to Retension Pharmaceuticals Chief Accounting Officer

According to the filing, Retension Pharmaceuticals, Inc. granted Robert Wong, its VP and Chief Accounting Officer, a stock option award covering 25,000 shares of common stock on November 2, 2026. The grant was made under the issuer's 2026 Equity Incentive Plan, as disclosed in the explanation of responses. The exercise price of the option is $11.30 per share, and the options carry an expiration date of November 2, 2036.

The filing describes the vesting terms as follows: "Twenty-five percent of the stock option vests on the first anniversary of the date of grant, with the remaining stock options vesting in 36 equal monthly increments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date." Prior to this transaction, the filing reflects no pre-existing derivative or non-derivative securities held by Wong, making the 25,000 options his entire reported beneficial ownership following the grant. The transaction code reported is "A," indicating an acquisition. Ownership is recorded as direct. The filing was signed by Alex Schwartz as attorney-in-fact on behalf of the reporting person.

Retension Pharmaceuticals, Inc. is listed on NASDAQ under the ticker RTSN. The filing was submitted as a one-reporting-person filing, with no joint or group filing indicated. No amendment date was listed, indicating this is an original filing.

What Was Disclosed

Retension Pharmaceuticals disclosed a stock option grant of 25,000 shares at an exercise price of $11.30 to VP and Chief Accounting Officer Robert Wong on November 2, 2026, under the company's 2026 Equity Incentive Plan, with a 10-year term and graduated vesting tied to continued service.